司库奇尤单抗在中重度斑块型银屑病患者中不论HLA-Cw6状态均显示高疗效:SUPREME研究
SUPREME是一项24周IIIb期研究,延长期至72周,评估司库奇尤单抗300 mg在HLA-Cw6阳性与阴性中重度慢性斑块型银屑病患者中的疗效与安全性。共纳入434例患者,第16周PASI 90应答率在Cw6阳性组为80.4%、Cw6阴性组为79.7%,两组差异无统计学意义。结论认为无需检测HLA-Cw6状态即可使用司库奇尤单抗治疗。
要点
- 第16周PASI 90应答率Cw6阳性组80.4% vs Cw6阴性组79.7%,差异0.76(95%CI -7.04至8.23)。
- 第16周绝对PASI评分Cw6阳性组1.36±3.58 vs Cw6阴性组1.18±2.29,两组无差异。
- 治疗中出现的不良事件发生率Cw6阳性组42.7% vs Cw6阴性组49.6%(P=0.295),无统计学显著差异。
核心结论
- 司库奇尤单抗治疗中重度斑块型银屑病疗效高且起效快,不论HLA-Cw6状态均高度有效,因此无需检测HLA-Cw6状态。
研究设计与样本
- SUPREME是一项24周IIIb期研究,延长期至72周,评估司库奇尤单抗300 mg在HLA-Cw6阳性与阴性中重度慢性斑块型银屑病患者中的疗效与安全性。
- 共纳入434例患者:185例(42.6%)为Cw6阳性,246例(56.7%)为Cw6阴性,3例未评估。
主要发现
- 平均±SD年龄为45.2±13.2岁(Cw6阳性组42.7±13.1;Cw6阴性组47.2±12.9)。
- 基线PASI评分两组相当:Cw6阳性组20.7±8.99;Cw6阴性组21.5±9.99(P=0.777)。
- 第16周PASI 90应答率Cw6阳性组80.4% vs Cw6阴性组79.7%,差异0.76(95%CI -7.04至8.23)。
- 第16周绝对PASI评分Cw6阳性组1.36±3.58 vs Cw6阴性组1.18±2.29,两组无差异。
- 治疗中出现的不良事件发生率Cw6阳性组42.7% vs Cw6阴性组49.6%(P=0.295),无统计学显著差异;总体安全性特征与既往报告一致。
临床怎么用
- 作者认为,使用司库奇尤单抗治疗时无需检测HLA-Cw6状态,因为不论HLA-Cw6状态如何均高度有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Understanding genetic variations is important in predicting treatment response and forms the basis for identifying new pharmacogenetic and pharmacogenomic targets for psoriasis treatment. There are limited data on the efficacy of secukinumab in relation to genetic markers. OBJECTIVES: To evaluate the efficacy and safety of secukinumab 300 mg in HLA-Cw6-positive (Cw6-POS) and HLA-Cw6-negative (Cw6-NEG) patients with moderate-to-severe chronic plaque-type psoriasis. METHODS: SUPREME was a 24-week, phase IIIb study with an extension period up to 72 weeks. Primary end point was Psoriasis Area Severity Index (PASI) 90 response rate after 16 weeks. RESULTS: In total, 434 patients were recruited: 185 (42·6%) were Cw6-POS and 246 (56·7%) were Cw6-NEG (three not assessed). Mean ± SD age was 45·2 ± 13·2 years (Cw6-POS 42·7 ± 13·1; Cw6-NEG 47·2 ± 12·9). The baseline PASI score was comparable between the cohorts [Cw6-POS 20·7 ± 8·99; Cw6-NEG 21·5 ± 9·99 (P = 0·777)]. At week 16, PASI 90 was achieved in 80·4% of Cw6-POS and 79·7% of Cw6-NEG patients (difference 0·76; 95% confidence interval -7·04 to 8·23). No differences in absolute PASI at week 16 (Cw6-POS 1·36 ± 3·58; Cw6-NEG 1·18 ± 2·29) were observed. The overall safety profile of secukinumab was consistent with that previously reported. No statistically significant difference was detected in the rate of treatment-emergent adverse events [Cw6-POS 42·7%; Cw6-NEG 49·6% (P = 0·295)]. A high PASI 90 response was achieved with secukinumab with a fast reduction in absolute PASI. CONCLUSIONS: Determination of HLA-Cw6 status for secukinumab therapy is unnecessary, as it is highly effective regardless of HLA-Cw6 status.
引用
- Costanzo A, Bianchi L, Flori ML, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018. PMID: 29704432. doi:10.1111/bjd.16705
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。